Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/47953 |
Resumo: | OBJECTIVE: The development of osteoporosis is associated with several risk factors, such as genetic structures that affect bone turnover and bone mass. The impact of genetic structures on osteoporosis is not known. Plasminogen activator inhibitor type-1 regulates the bone matrix and bone balance. This study assessed the correlation between plasminogen activator inhibitor type-1 gene 4G/5G polymorphisms and osteoporosis in a population of Turkish women. METHODS: A total of 195 postmenopausal female patients who were diagnosed with osteoporosis (Group I) based on bone mineral density measurements via dual-energy x-ray absorptiometry and 90 females with no osteoporosis (Group II) were included in this study. Correlations between PAI-1 gene 4G/5G polymorphisms and osteoporosis were investigated through the identification of PAI-1 gene 4G/5G polymorphism genotypes using the polymerase chain reaction. RESULTS: No significant differences in the genotype and allele frequency of 4G/5G plasminogen activator inhibitor type-1 polymorphisms were observed between the two groups, and both groups exhibited the most frequently observed 4G5G genotype. CONCLUSION: No correlation between the development of osteoporosis in the female Turkish population and 4G/5G plasminogen activator inhibitor type-1 gene polymorphisms was observed. |
id |
USP-19_1a5251bd0450617f472e4c38435fdc71 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/47953 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish womenOsteoporosisPolymorphismPlasminogen Activator Inhibitor Type-1 (PAI-1) GeneBone Mineral DensityTurkish WomenOBJECTIVE: The development of osteoporosis is associated with several risk factors, such as genetic structures that affect bone turnover and bone mass. The impact of genetic structures on osteoporosis is not known. Plasminogen activator inhibitor type-1 regulates the bone matrix and bone balance. This study assessed the correlation between plasminogen activator inhibitor type-1 gene 4G/5G polymorphisms and osteoporosis in a population of Turkish women. METHODS: A total of 195 postmenopausal female patients who were diagnosed with osteoporosis (Group I) based on bone mineral density measurements via dual-energy x-ray absorptiometry and 90 females with no osteoporosis (Group II) were included in this study. Correlations between PAI-1 gene 4G/5G polymorphisms and osteoporosis were investigated through the identification of PAI-1 gene 4G/5G polymorphism genotypes using the polymerase chain reaction. RESULTS: No significant differences in the genotype and allele frequency of 4G/5G plasminogen activator inhibitor type-1 polymorphisms were observed between the two groups, and both groups exhibited the most frequently observed 4G5G genotype. CONCLUSION: No correlation between the development of osteoporosis in the female Turkish population and 4G/5G plasminogen activator inhibitor type-1 gene polymorphisms was observed.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2012-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/4795310.6061/clinics/2012(11)13Clinics; Vol. 67 No. 11 (2012); 1299-1302Clinics; v. 67 n. 11 (2012); 1299-1302Clinics; Vol. 67 Núm. 11 (2012); 1299-13021980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/47953/51693Ozgen, MerihCosan, Didem TurgutDoganer, FulyaSoyocak, AhuArmagan, OnurGunes, Hasan VeysiDegirmenci, IrfanOzkara, Gulsah OgutlerMutlu, Fezan Sahininfo:eu-repo/semantics/openAccess2012-12-13T11:04:15Zoai:revistas.usp.br:article/47953Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-12-13T11:04:15Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women |
title |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women |
spellingShingle |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women Ozgen, Merih Osteoporosis Polymorphism Plasminogen Activator Inhibitor Type-1 (PAI-1) Gene Bone Mineral Density Turkish Women |
title_short |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women |
title_full |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women |
title_fullStr |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women |
title_full_unstemmed |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women |
title_sort |
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women |
author |
Ozgen, Merih |
author_facet |
Ozgen, Merih Cosan, Didem Turgut Doganer, Fulya Soyocak, Ahu Armagan, Onur Gunes, Hasan Veysi Degirmenci, Irfan Ozkara, Gulsah Ogutler Mutlu, Fezan Sahin |
author_role |
author |
author2 |
Cosan, Didem Turgut Doganer, Fulya Soyocak, Ahu Armagan, Onur Gunes, Hasan Veysi Degirmenci, Irfan Ozkara, Gulsah Ogutler Mutlu, Fezan Sahin |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Ozgen, Merih Cosan, Didem Turgut Doganer, Fulya Soyocak, Ahu Armagan, Onur Gunes, Hasan Veysi Degirmenci, Irfan Ozkara, Gulsah Ogutler Mutlu, Fezan Sahin |
dc.subject.por.fl_str_mv |
Osteoporosis Polymorphism Plasminogen Activator Inhibitor Type-1 (PAI-1) Gene Bone Mineral Density Turkish Women |
topic |
Osteoporosis Polymorphism Plasminogen Activator Inhibitor Type-1 (PAI-1) Gene Bone Mineral Density Turkish Women |
description |
OBJECTIVE: The development of osteoporosis is associated with several risk factors, such as genetic structures that affect bone turnover and bone mass. The impact of genetic structures on osteoporosis is not known. Plasminogen activator inhibitor type-1 regulates the bone matrix and bone balance. This study assessed the correlation between plasminogen activator inhibitor type-1 gene 4G/5G polymorphisms and osteoporosis in a population of Turkish women. METHODS: A total of 195 postmenopausal female patients who were diagnosed with osteoporosis (Group I) based on bone mineral density measurements via dual-energy x-ray absorptiometry and 90 females with no osteoporosis (Group II) were included in this study. Correlations between PAI-1 gene 4G/5G polymorphisms and osteoporosis were investigated through the identification of PAI-1 gene 4G/5G polymorphism genotypes using the polymerase chain reaction. RESULTS: No significant differences in the genotype and allele frequency of 4G/5G plasminogen activator inhibitor type-1 polymorphisms were observed between the two groups, and both groups exhibited the most frequently observed 4G5G genotype. CONCLUSION: No correlation between the development of osteoporosis in the female Turkish population and 4G/5G plasminogen activator inhibitor type-1 gene polymorphisms was observed. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-11-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/47953 10.6061/clinics/2012(11)13 |
url |
https://www.revistas.usp.br/clinics/article/view/47953 |
identifier_str_mv |
10.6061/clinics/2012(11)13 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/47953/51693 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 67 No. 11 (2012); 1299-1302 Clinics; v. 67 n. 11 (2012); 1299-1302 Clinics; Vol. 67 Núm. 11 (2012); 1299-1302 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222759202062336 |